Viridian Therapeutics Secures $889 Million Financing and Submits BLA for Veligrotug
I'm PortAI, I can summarize articles.
Viridian Therapeutics Inc. has secured up to $889 million in financing through various arrangements and amended its credit facility with Hercules Capital for an additional $300 million. The company submitted a Biologics License Application for veligrotug for thyroid eye disease, aiming for a U.S. launch in mid-2026. Upcoming data readouts for VRDN-003 are expected in early 2026. Viridian anticipates that its current cash and expected revenues will support its business plans until profitability.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments